EA202191256A1 - Способы лечения рака на моделях, имеющих мутации esr1 - Google Patents
Способы лечения рака на моделях, имеющих мутации esr1Info
- Publication number
- EA202191256A1 EA202191256A1 EA202191256A EA202191256A EA202191256A1 EA 202191256 A1 EA202191256 A1 EA 202191256A1 EA 202191256 A EA202191256 A EA 202191256A EA 202191256 A EA202191256 A EA 202191256A EA 202191256 A1 EA202191256 A1 EA 202191256A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- estrogen receptor
- receptor alpha
- methods
- models
- Prior art date
Links
- 102100038595 Estrogen receptor Human genes 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 title abstract 2
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 title 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- SIFNOOUKXBRGGB-AREMUKBSSA-N (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1=CC(CCNCC)=CC=C1CN(CC)C1=CC(OC)=CC=C1[C@H]1CC2=CC=C(O)C=C2CC1 SIFNOOUKXBRGGB-AREMUKBSSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 229950005473 elacestrant Drugs 0.000 abstract 1
- 201000002511 pituitary cancer Diseases 0.000 abstract 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776338P | 2018-12-06 | 2018-12-06 | |
| PCT/US2019/064980 WO2020118202A1 (en) | 2018-12-06 | 2019-12-06 | Methods for treating cancer in models harboring esr1 mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191256A1 true EA202191256A1 (ru) | 2021-10-06 |
Family
ID=69158304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191256A EA202191256A1 (ru) | 2018-12-06 | 2019-12-06 | Способы лечения рака на моделях, имеющих мутации esr1 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220016052A1 (https=) |
| EP (1) | EP3890835A1 (https=) |
| JP (2) | JP7497353B2 (https=) |
| KR (1) | KR20210100135A (https=) |
| AU (1) | AU2019392908B2 (https=) |
| BR (1) | BR112021010141A2 (https=) |
| CA (1) | CA3121918A1 (https=) |
| EA (1) | EA202191256A1 (https=) |
| IL (1) | IL283655A (https=) |
| JO (1) | JOP20210138B1 (https=) |
| MA (1) | MA54393A (https=) |
| MX (1) | MX2021006412A (https=) |
| MY (1) | MY208702A (https=) |
| PH (1) | PH12021551327A1 (https=) |
| SG (1) | SG11202105915UA (https=) |
| UA (1) | UA129588C2 (https=) |
| WO (1) | WO2020118202A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3834824T3 (fi) * | 2014-03-28 | 2025-12-05 | Univ Duke | Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla |
| JP7019422B2 (ja) * | 2015-04-29 | 2022-02-15 | ラジウス ファーマシューティカルズ，インコーポレイテッド | 癌を治療するための方法 |
-
2019
- 2019-12-06 KR KR1020217020309A patent/KR20210100135A/ko not_active Ceased
- 2019-12-06 CA CA3121918A patent/CA3121918A1/en active Pending
- 2019-12-06 WO PCT/US2019/064980 patent/WO2020118202A1/en not_active Ceased
- 2019-12-06 BR BR112021010141-1A patent/BR112021010141A2/pt unknown
- 2019-12-06 EA EA202191256A patent/EA202191256A1/ru unknown
- 2019-12-06 AU AU2019392908A patent/AU2019392908B2/en active Active
- 2019-12-06 UA UAA202103001A patent/UA129588C2/uk unknown
- 2019-12-06 SG SG11202105915UA patent/SG11202105915UA/en unknown
- 2019-12-06 MY MYPI2021003130A patent/MY208702A/en unknown
- 2019-12-06 MX MX2021006412A patent/MX2021006412A/es unknown
- 2019-12-06 JP JP2021531817A patent/JP7497353B2/ja active Active
- 2019-12-06 PH PH1/2021/551327A patent/PH12021551327A1/en unknown
- 2019-12-06 US US17/299,361 patent/US20220016052A1/en not_active Abandoned
- 2019-12-06 EP EP19835569.5A patent/EP3890835A1/en not_active Withdrawn
- 2019-12-06 MA MA054393A patent/MA54393A/fr unknown
-
2021
- 2021-06-02 IL IL283655A patent/IL283655A/en unknown
- 2021-06-06 JO JOJO/P/2021/0138A patent/JOP20210138B1/ar active
-
2024
- 2024-05-29 JP JP2024086821A patent/JP2024101017A/ja active Pending
-
2025
- 2025-04-21 US US19/184,210 patent/US20250241875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3890835A1 (en) | 2021-10-13 |
| JP2022511497A (ja) | 2022-01-31 |
| KR20210100135A (ko) | 2021-08-13 |
| IL283655A (en) | 2021-07-29 |
| CA3121918A1 (en) | 2020-06-11 |
| AU2019392908A1 (en) | 2021-06-10 |
| MX2021006412A (es) | 2021-07-21 |
| WO2020118202A1 (en) | 2020-06-11 |
| MY208702A (en) | 2025-05-25 |
| JOP20210138B1 (ar) | 2025-10-01 |
| JP2024101017A (ja) | 2024-07-26 |
| BR112021010141A2 (pt) | 2021-08-24 |
| UA129588C2 (uk) | 2025-06-11 |
| US20220016052A1 (en) | 2022-01-20 |
| JP7497353B2 (ja) | 2024-06-10 |
| SG11202105915UA (en) | 2021-07-29 |
| MA54393A (fr) | 2021-10-13 |
| US20250241875A1 (en) | 2025-07-31 |
| JOP20210138A1 (ar) | 2023-01-30 |
| AU2019392908B2 (en) | 2025-02-20 |
| PH12021551327A1 (en) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210137A1 (ar) | طرق علاج سرطان مقاومة لمثبطات cdk4/6 | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| SA521421973B1 (ar) | عامل مضاد لمستقبل crf1، ومستحضرات صيدلانية وأشكال صلبة منها لعلاج فرط التنسج الكظري الخلقي | |
| MX2020013335A (es) | Metodos novedosos. | |
| MX2020009668A (es) | Métodos novedosos. | |
| MX2017015226A (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| UA124238U (uk) | Спосіб лікування раку молочної залози | |
| MX419719B (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
| MX2017009047A (es) | Regimen de dosificacion para antagonistas de madcam. | |
| JP2019532047A5 (https=) | ||
| EA202092036A1 (ru) | Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a | |
| MX2023014563A (es) | Combinacion de un inhibidor de braf particular (interruptor de paradoja) y un antagonista de union al eje de pd-1 para su uso en el tratamiento de cancer. | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| EA202193178A1 (ru) | Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина | |
| EA201891289A1 (ru) | Циклическая терапия с применением 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона | |
| EA202191256A1 (ru) | Способы лечения рака на моделях, имеющих мутации esr1 | |
| ZA202108094B (en) | Mirikizumab for use in a method of treating crohn's disease | |
| MX2021003274A (es) | Combinacion farmaceutica para el tratamiento de cancer. | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| MX2023012415A (es) | Metodos de uso del dantroleno para tratar la exposicion a agente nervioso. | |
| PH12021551437A1 (en) | Estrogen receptor antagonist | |
| EA202190458A1 (ru) | Составы, содержащие дендример |